Nanomedicines,
while having been approved for cancer therapy, present
many challenges such as low stability, rapid clearance, and nonspecificity
leading to off-target toxicity. Cubosomes are porous lyotropic liquid
crystalline nanoparticles that have shown great premise as drug delivery
vehicles; however, their behavior
in vivo
is largely
underexplored, hindering clinical translation. Here, we have engineered
cubosomes based on the space group
Im
3
m
that are loaded with copper acetylacetonate as a model drug, and
their surfaces are functionalized for the first time with Affimer
proteins via copper-free click chemistry to actively target overexpressed
carcinoembryonic antigens on LS174T colorectal cancer cells. Unlike
nontargeted cubosomes, Affimer tagged cubosomes showed preferential
accumulation in cancer cells compared to normal cells not only
in vitro
(2D monolayer cell culture and 3D spheroid models)
but also
in vivo
in colorectal cancer mouse xenografts,
while exhibiting low nonspecific absorption and toxicity in other
vital organs. Cancerous spheroids had maximum cell death compared
to noncancerous cells upon targeted delivery. Xenografts subjected
to targeted drug-loaded cubosomes showed a 5–7-fold higher
drug accumulation in the tumor tissue compared to the liver, kidneys,
and other vital organs, a significant decrease in tumor growth, and
an increased survival rate compared to the nontargeted group. This
work encompasses the first thorough preclinical investigation of Affimer
targeted cubosomes as a cancer therapeutic.